Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

INTRODUCTION: Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 BRIGHTE trial in heavily treatment-experienced (HTE) adults failing their current antiretroviral regimen. Here, we report 240-week effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aberg, Judith A., Shepherd, Bronagh, Wang, Marcia, Madruga, Jose V., Mendo Urbina, Fernando, Katlama, Christine, Schrader, Shannon, Eron, Joseph J., Kumar, Princy N., Sprinz, Eduardo, Gartland, Margaret, Chabria, Shiven, Clark, Andrew, Pierce, Amy, Lataillade, Max, Tenorio, Allan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581994/
https://www.ncbi.nlm.nih.gov/pubmed/37751019
http://dx.doi.org/10.1007/s40121-023-00870-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581994/
https://www.ncbi.nlm.nih.gov/pubmed/37751019
http://dx.doi.org/10.1007/s40121-023-00870-6

Ejemplares similares